Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Clinical Outlook
  • Published:

Evolving landscape of nasopharyngeal carcinoma therapy

Nature Cancer volume 6, pages 1480–1482 (2025)Cite this article

Subjects

An Author Correction to this article was published on 10 October 2025

This article has been updated

Propelled by a growing understanding of nasopharyngeal carcinoma pathogenesis through elucidation of its genomic and immune landscape, therapy has progressed from radiotherapy alone to combined chemotherapy and immunotherapy. This Clinical Outlook focuses on recent milestones and future directions for patients with nasopharyngeal carcinoma.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: A timeline of NPC therapy.

Change history

References

  1. Wong, K. C. W. et al. Nat. Rev. Clin. Oncol. 18, 679–695 (2021).

    Article  CAS  PubMed  Google Scholar 

  2. Bruce, J. P. et al. Nat. Commun. 12, 4193 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Chan, K. C. A. et al. N. Engl. J. Med. 377, 513–522 (2017).

    Article  CAS  PubMed  Google Scholar 

  4. Lv, J. et al. Cancer Cell 42, 1401–1414.e4 (2024).

    Article  CAS  PubMed  Google Scholar 

  5. Gong, L. et al. Nat. Commun. 12, 1540 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Liu, Y. et al. Nat. Commun. 15, 7713 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Colevas, A. D. et al. Clin. Cancer Res. 31, 815–823 (2025).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Ma, Y. et al. Nat. Med. 31, 1949–1957 (2025).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Mai, H.-Q. et al. JAMA 330, 1961–1970 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Yang, Y. et al. Cancer Cell 41, 1061–1072.e4 (2023).

    Article  CAS  PubMed  Google Scholar 

  11. Yang, Y. et al. Lancet Oncol. 22, 1162–1174 (2021).

    Article  CAS  PubMed  Google Scholar 

  12. Chan, A. T. C. et al. Ann. Oncol. 34, 251–261 (2023).

    Article  CAS  PubMed  Google Scholar 

  13. Chong, W.-Q. et al. Lancet Oncol. 26, 175–186 (2025).

    Article  CAS  PubMed  Google Scholar 

  14. Liu, X. et al. Lancet 403, 2720–2731 (2024).

    Article  CAS  PubMed  Google Scholar 

  15. Liang, Y.-L. et al. JAMA 333, 1589–1598 (2025).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Author notes

  1. These authors jointly supervised this work: Boon Cher Goh, Brigette B. Y. Ma.

Authors and Affiliations

  1. Department of Clinical Oncology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China

    Kar Wei Chin & Brigette B. Y. Ma

  2. Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore

    Wan-Qin Chong & Boon Cher Goh

  3. Cancer Science Institute of Singapore, Singapore, Singapore

    Boon Cher Goh

  4. Department of Pharmacology, National University of Singapore, Singapore, Singapore

    Boon Cher Goh

  5. State Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong SAR, China

    Brigette B. Y. Ma

Authors
  1. Kar Wei Chin
    View author publications

    Search author on:PubMed Google Scholar

  2. Wan-Qin Chong
    View author publications

    Search author on:PubMed Google Scholar

  3. Boon Cher Goh
    View author publications

    Search author on:PubMed Google Scholar

  4. Brigette B. Y. Ma
    View author publications

    Search author on:PubMed Google Scholar

Corresponding authors

Correspondence to Boon Cher Goh or Brigette B. Y. Ma.

Ethics declarations

Competing interests

B.C.G. declares research support from MSD, Taiho, Gilead and Adagene. B.C.G. is the principal investigator for clinical trials with Bayer healthcare, Alx pharmaceuticals, Boehinger Ingelheim, Novartis, Pfizer and MSD. B.B.Y.M. is an advisory board member and receives speaker’s honoraria from Bristol Myers Squibb, Merck Serono, MSD and Novartis, and is a consultant for Y-Biologics. W.-Q.C. declares research funding from MSD, honoraria from MSD and Ipsen, consulting fees from Merck, Diethelm, KellerSiberHegner and Junshi Biosciences. K.W.C. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chin, K.W., Chong, WQ., Goh, B.C. et al. Evolving landscape of nasopharyngeal carcinoma therapy. Nat Cancer 6, 1480–1482 (2025). https://doi.org/10.1038/s43018-025-01045-7

Download citation

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s43018-025-01045-7

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer